2016

10732 bookmarks
Newest
Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial - PubMed
Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial - PubMed
AMG Charitable Foundation, Tackle ALS, the ALS Association, ALS Finding a Cure, the Muscular Dystrophy Association, ALS ONE, the Arthur M Blank Family Foundation, I AM ALS, Tambourine ALS Collaborative, and other community fundraising initiatives and donors. Study drug and partial regimen-related fu …
·pubmed.ncbi.nlm.nih.gov·
Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial - PubMed
Creatine monohydrate pilot in Alzheimer's: Feasibility, brain creatine, and cognition - Smith - 2025 - Alzheimer's & Dementia: Translational Research & Clinical Interventions - Wiley Online Library
Creatine monohydrate pilot in Alzheimer's: Feasibility, brain creatine, and cognition - Smith - 2025 - Alzheimer's & Dementia: Translational Research & Clinical Interventions - Wiley Online Library
BACKGROUND Preclinical studies suggest that creatine monohydrate (CrM) improves cognition and Alzheimer's disease (AD) biomarkers. However, there is currently no clinical evidence demonstrating the ...
·alz-journals.onlinelibrary.wiley.com·
Creatine monohydrate pilot in Alzheimer's: Feasibility, brain creatine, and cognition - Smith - 2025 - Alzheimer's & Dementia: Translational Research & Clinical Interventions - Wiley Online Library
Parkinsons New Zealand - YouTube
Parkinsons New Zealand - YouTube
Parkinson's New Zealand provides information, education and support to people living with Parkinson's, care partners and healthcare professionals. Parkinson's is a progressive neurological condition which affects over 12,000 New Zealanders. Although it cannot be cured, treatment is available.
·youtube.com·
Parkinsons New Zealand - YouTube
OmegaXL
OmegaXL
OmegaXL is a powerful natural supplement shown in clinical research to support joint comfort and function? It contains more than 30 healthy fatty acids, including DHA and EPA. Give it a try, OmegaXL works!
·omegaxl.com·
OmegaXL
Parkinson’s Disease Education - YouTube
Parkinson’s Disease Education - YouTube
This channel is dedicated to helping Persons with Parkinson's Disease to become Parkinson's Warriors fighting their disease wielding the weapon of knowledge about PD and the impact that it has on daily living. Book 1:1 consultation with a Parkinson's Disease Expert here: https://clarity.fm/pdeducation Explore channel memberships here: YouTube: https://www.youtube.com/channel/UC0g3abv8hkaqZbGD8y1dfYQ/join Patreon: https://www.patreon.com/pdeducation If you have products that you would like for me to review on the channel please send them here: Parkinson's Disease Education P.O. Box 1678 Broken Arrow, OK 74013
·youtube.com·
Parkinson’s Disease Education - YouTube
! ! Rethinking Parkinson's disease: could dopamine reduction therapy have clinical utility? | Journal of Neurology
! ! Rethinking Parkinson's disease: could dopamine reduction therapy have clinical utility? | Journal of Neurology
Following reports of low striatal dopamine content in Parkinson’s disease, levodopa was shown to rapidly reverse hypokinesis, establishing the model of disease as one of dopamine deficiency. Dopaminergic therapy became standard of care, yet it failed to reverse the disease, suggesting the understanding of disease was incomplete. The literature suggests the potential for toxicity of dopamine and its metabolites, perhaps more relevant given the recent evidence for elevated cytosolic dopamine levels in the dopaminergic neurons of people with Parkinson’s. To understand the relevance of these data, multiple investigations are reviewed that tested dopamine reduction therapy as an alternative to dopaminergic agents. The data from use of an inhibitor of dopamine synthesis in experimental models suggest that such an approach could reverse disease pathology, which suggests that cytosolic dopamine excess is a primary driver of disease. These data support clinical investigation of dopamine reduction therapy for Parkinson’s disease. Doing so will determine whether these experimental models are predictive and this treatment strategy is worth pursuing further. If clinical data are positive, it could warrant reconsideration of our disease model and treatment strategies, including a shift from dopaminergic to dopamine reduction treatment of the disease.
·link.springer.com·
! ! Rethinking Parkinson's disease: could dopamine reduction therapy have clinical utility? | Journal of Neurology
! ! Right Brain Bio
! ! Right Brain Bio
Right Brain Bio is developing a data-driven treatment for Parkinson's - one so revolutionary that it will transform disease understanding and treatment.
·rightbrainbio.com·
! ! Right Brain Bio